|
タカダ タクマ
TAKADA Takuma
髙田 卓磨 所属 医学研究科 医学研究科 (医学部医学科をご参照ください) 職種 非常勤講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study. |
| 掲載誌名 | 正式名：Circulation journal : official journal of the Japanese Circulation Society 略 称：Circ J ISSNコード：13474820/13469843 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.online |
| 著者・共著者 | Fujiki Shinya, Yamashita Yugo, Morimoto Takeshi, Muraoka Nao, Umetsu Michihisa, Nishimoto Yuji, Takada Takuma, Ogihara Yoshito, Nishikawa Tatsuya, Ikeda Nobutaka, Otsui Kazunori, Sueta Daisuke, Tsubata Yukari, Shoji Masaaki, Shikama Ayumi, Hosoi Yutaka, Tanabe Yasuhiro, Chatani Ryuki, Tsukahara Kengo, Nakanishi Naohiko, Kim Kitae, Ikeda Satoshi, Kimura Takeshi, Inomata Takayuki, |
| 発行年月 | 2024/09 |
| 概要 | BACKGROUND:The ONCO DVT study demonstrated potential benefits of extended edoxaban treatment in patients with isolated distal deep vein thrombosis in terms of thrombotic risk. However, the risk-benefit balance in patients with anemia remains unclear.METHODS AND RESULTS:This prespecified subgroup analysis included 601 patients, divided into anemia (n=402) and no-anemia (n=199) groups. The primary endpoint was symptomatic recurrent venous thromboembolism (VTE) or VTE-related death. Anemia was defined as hemoglobin <12 g/dL for women and <13 g/dL for men. In the anemia subgroup, the primary endpoint occurred in 3 (1.5%) and 17 (8.4%) patients in the 12- and 3-month edoxaban treatment groups, respectively (odds ratio [OR] 0.17; 95% confidence interval [CI] 0.05-0.58), compared with 0 and 5 (4.9%) patients, respectively, in the no-anemia subgroup (P interaction=0.997). Major bleeding occurred in 26 (13.1%) and 17 (8.4%) patients with anemia in the 12- and 3-month edoxaban treatment groups, respectively (OR 1.64; 95% CI 0.86-3.14), compared with 2 (2.1%) and 5 (4.9%) patients without anemia (OR 0.67; 95% CI 0.26-1.73; P interaction=0.13).CONCLUSIONS:Regardless of the presence of anemia, edoxaban treatment for 12 months was superior to treatment for 3 months in reducing thrombotic events, whereas the risk of major bleeding did not differ significantly between the 2 treatment groups. |
| DOI | 10.1253/circj.CJ-24-0571 |
| PMID | 39293971 |